Issue link: https://viewer.e-digitaledition.com/i/125960
"Our goal here is to try to attack the cancer in as many different ways as possible. Before treatments become standard clinical practice, they must go through clinical trials in a place dedicated to that kind of clinical research — like Montefiore Einstein Center for Cancer Care." — Stuart Packer, M.D., Clinical Director, Weiler Oncology Service and Director, Melanoma/ Sarcoma Program, Montefiore Einstein Center for Cancer Care, and assistant professor, Karthik Krishnamurthy, D.O., performs a skin biopsy with Patricia Keys, LPN. Department of Medicine (Oncology), Albert Einstein most important, treatment with IL-2 healthy tissues. The problem is CTLA-4 College of Medicine doesn't affect whether the patient can go on to receive more standard treatments. criteria for IL-2 therapy are predicated on the patient's performance status and stage of disease. Patients in good overall health with no significant cardiac or pulmonary disease may be candidates for IL-2 therapy. The results from IL-2 therapy are almost always seen within several weeks, and Unchecking the Immune System While IL-2 works to augment the immune system, ipilimumab works to keep it going. CTLA-4 is a molecule located on T-cells that prevents them from assaulting the body's normal Dr. Packer and Katia Papalezova, M.D., collaborate on a patient case. can suppress the immune system's attack on cancer as well. Approved by the FDA in 2011, ipilimumab blocks the CTLA-4 response, enabling the immune system to effectively identify, target and attack melanoma tumor cells. Ipilimumab is typically administered via four courses of intravenous infusion once every three weeks. Although response rates with ipilimumab are modest, some patients may achieve longlasting, durable remissions. Ipilimumab can result in side effects, such as colitis, diarrhea, endocrine deficiencies, fatigue and skin rash, due to its potency. Montefiore Einstein Center for Cancer Care's experienced providers are trained to identify and manage these side effects. Innovation for Gene Mutations A subgroup of patients with melanoma has tumors that express the BRAF V600E gene mutation. BRAF proteins are typically involved in the regulation of cell growth, but in nearly half of all patients with late-stage melanomas, a mutation of this gene causes the tumor cells to grow quickly, according to the American Cancer Society MDNEWS.COM I MD NEWS Lower Hudson/Bronx |7

